Harvard Medical School, Boston, Massachusetts.
Infection Control Unit, Massachusetts General Hospital, Boston.
JAMA. 2019 Jan 15;321(2):188-199. doi: 10.1001/jama.2018.19283.
β-Lactam antibiotics are among the safest and most effective antibiotics. Many patients report allergies to these drugs that limit their use, resulting in the use of broad-spectrum antibiotics that increase the risk for antimicrobial resistance and adverse events.
Approximately 10% of the US population has reported allergies to the β-lactam agent penicillin, with higher rates reported by older and hospitalized patients. Although many patients report that they are allergic to penicillin, clinically significant IgE-mediated or T lymphocyte-mediated penicillin hypersensitivity is uncommon (<5%). Currently, the rate of IgE-mediated penicillin allergies is decreasing, potentially due to a decreased use of parenteral penicillins, and because severe anaphylactic reactions to oral amoxicillin are rare. IgE-mediated penicillin allergy wanes over time, with 80% of patients becoming tolerant after a decade. Cross-reactivity between penicillin and cephalosporin drugs occurs in about 2% of cases, less than the 8% reported previously. Some patients have a medical history that suggests they are at a low risk for developing an allergic reaction to penicillin. Low-risk histories include patients having isolated nonallergic symptoms, such as gastrointestinal symptoms, or patients solely with a family history of a penicillin allergy, symptoms of pruritus without rash, or remote (>10 years) unknown reactions without features suggestive of an IgE-mediated reaction. A moderate-risk history includes urticaria or other pruritic rashes and reactions with features of IgE-mediated reactions. A high-risk history includes patients who have had anaphylaxis, positive penicillin skin testing, recurrent penicillin reactions, or hypersensitivities to multiple β-lactam antibiotics. The goals of antimicrobial stewardship are undermined when reported allergy to penicillin leads to the use of broad-spectrum antibiotics that increase the risk for antimicrobial resistance, including increased risk of methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus. Broad-spectrum antimicrobial agents also increase the risk of developing Clostridium difficile (also known as Clostridioides difficile) infection. Direct amoxicillin challenge is appropriate for patients with low-risk allergy histories. Moderate-risk patients can be evaluated with penicillin skin testing, which carries a negative predictive value that exceeds 95% and approaches 100% when combined with amoxicillin challenge. Clinicians performing penicillin allergy evaluation need to identify what methods are supported by their available resources.
Many patients report they are allergic to penicillin but few have clinically significant reactions. Evaluation of penicillin allergy before deciding not to use penicillin or other β-lactam antibiotics is an important tool for antimicrobial stewardship.
β-内酰胺类抗生素是最安全和最有效的抗生素之一。许多患者报告对这些药物过敏,这限制了它们的使用,导致使用广谱抗生素,增加了对抗微生物药物耐药性和不良事件的风险。
约 10%的美国人口报告对β-内酰胺类药物青霉素过敏,年龄较大和住院患者的报告率更高。尽管许多患者报告说他们对青霉素过敏,但临床上 IgE 介导或 T 淋巴细胞介导的青霉素过敏并不常见(<5%)。目前,IgE 介导的青霉素过敏率正在下降,可能是由于注射用青霉素的使用减少,以及口服阿莫西林引起严重过敏反应的罕见。IgE 介导的青霉素过敏随时间减弱,80%的患者在十年后变得耐受。青霉素和头孢菌素类药物之间发生交叉反应的比例约为 2%,低于之前报告的 8%。一些患者有病史表明他们发生青霉素过敏反应的风险较低。低风险病史包括仅出现非过敏性症状(如胃肠道症状)的患者,或仅有青霉素过敏家族史、无皮疹瘙痒或多年前(>10 年)未知但无 IgE 介导反应特征的反应的患者。中风险病史包括荨麻疹或其他瘙痒性皮疹和具有 IgE 介导反应特征的反应。高风险病史包括发生过过敏反应、青霉素皮试阳性、青霉素反复反应或对多种β-内酰胺类抗生素过敏的患者。当报告的青霉素过敏导致使用增加抗菌药物耐药性的广谱抗生素时,会破坏抗菌药物管理的目标,包括增加耐甲氧西林金黄色葡萄球菌和万古霉素耐药肠球菌的风险。广谱抗菌药物也会增加艰难梭菌(也称为艰难梭菌)感染的风险。有低风险过敏史的患者可进行直接阿莫西林挑战。中风险患者可通过青霉素皮试进行评估,该方法的阴性预测值>95%,当与阿莫西林挑战结合时接近 100%。进行青霉素过敏评估的临床医生需要确定他们的可用资源支持哪些方法。
许多患者报告对青霉素过敏,但很少有临床意义上的反应。在决定不使用青霉素或其他β-内酰胺类抗生素之前,对青霉素过敏进行评估是抗菌药物管理的重要工具。